ABSTRACT
SARS-COV-2 evolution generates different variants and drives the pandemic. As the current main driver, δ variant bears little resemblance to the other three variants of concern, raising the question what features future variants of concern may possess. To address this important question, I compared different variant genomes and specifically analyzed δ genomes in the GISAID database for potential clues. The analysis revealed that δ genomes identified in India by April 2021 form four different groups (referred to as δ1, δ2, δ3 and δ4) with signature spike, nucleocapsid and NSP3 substitutions defining each group. Since May 2021, δ1 has gradually overtaken all other subvariants and become the dominant pandemic driver, whereas δ2 has played a less prominent role and the remaining two (δ3 and δ4) are insignificant. This group composition and variant transition are also apparent across Europe. In the United Kingdom, δ1 has quickly become predominant and is the sole pandemic driver underlying the current wave of COVID-19 cases. Alarmingly, δ1 subvariant has evolved further in the country and yielded a sublineage encoding spike V36F, A222V and V1264L. These substitutions may make the sublineage more virulent than δ1 itself. In the rest of Europe, δ1 is also the main pandemic driver, but δ2 still plays a role. In many European countries, there is a δ1 sublineage encoding spike T29A, T250I and Q613H. This sublineage originated from Morocco and has been a key pandemic driver there. Therefore, δ variant drives the pandemic in India and across Europe mainly through δ1 and δ2, with the former acquiring additional substitutions and yielding sublineages with the potential to drive the pandemic further. These results suggest a continuously branching model by which δ variant evolves and generates more virulent subvariants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by funds from Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada (NSERC) and Compute Canada (to X.J.Y.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
SARS-COV-2 genome sequences were downloaded the GISAID database (https://www.gisaid.org/). Pandemic and vaccination data were downloaded from the Our World in Data website (https://ourworldindata.org/explorers/coronavirus-data-explorer?zoomToSelection=true&time=2020-03-01..latest&facet=none&pickerSort=desc&pickerMetric=total_cases&Metric=Confirmed+cases&Interval=Cumulative&Relative+to+Population=false&Align+outbreaks=false&country=~OWID_WRL)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
